Dergiler / art / 2018 / Cilt: 33 - Sayı: 2

Fibromyalgia Syndrome and Vitiligo: A Novel Association

Dergi
art
Sayfa
174–180
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This may suggest that early diagnosis of FMS in vitiligo patients may help in early treatment and subsequently improve patients’ quality of life.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: This study aims to assess the relationship between fibromyalgia syndrome (FMS) and vitiligo in Iraqi patients and evaluate the predictors of this relationship, if present.
📊
Temel Bulgular & Veri:Patients and methods: The case-control study included 100 Iraqi patients (46 males, 54 females; mean age 30.4±14 years; range 15 to 65 years) with vitiligo and 200 age- and sex-matched healthy controls (74 males, 126 females; mean age 30.3±9.4 years; range 15 to 62 years).
💡
Sonuç & Katkı:This may suggest that early diagnosis of FMS in vitiligo patients may help in early treatment and subsequently improve patients’ quality of life.
🔬Tür:Araştırma Makalesi
📍Kapsam:2012 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: This study aims to assess the relationship between fibromyalgia syndrome (FMS) and vitiligo in Iraqi patients and evaluate the predictors of this relationship, if present. Patients and methods: The case-control study included 100 Iraqi patients (46 males, 54 females; mean age 30.4±14 years; range 15 to 65 years) with vitiligo and 200 age- and sex-matched healthy controls (74 males, 126 females; mean age 30.3±9.4 years; range 15 to 62 years). Baseline characteristics of patients and controls were recorded. The 2012 Canadian Guidelines criteria were used for the diagnosis of FMS and applied to all patients and controls. Results: Prevalence of FMS in vitiligo patients and controls was 12% and 7%, respectively (p=0.15, odds ratio=1.8, 95% confidence interval=0.8-4.08). FMS symptoms in vitiligo patients were fatigue (46%), diffuse body pain (34%), sleep disturbance (33%), cognitive dysfunction (30%), and mood disorders (23%), while visceral involvements were central nervous system (52%), skin (35%), gastrointestinal tract (32%), cardiovascular systemrespiratory system (16%), genitourinary tract (8%), and ear nose throat (7%). Of vitiligo patients, FMS was significantly more common among females (22.2%) compared to none among males (0%) (p 0/05). No significant association was found between FMS in vitiligo patients and age, disease duration, type of vitiligo, use of any immunosuppressant and Body Mass Index (p>0.05). Conclusion: Fibromyalgia syndrome was more prevalent in vitiligo patients compared to controls, which was clinically important but statistically not significant. There was a significant association between FMS in vitiligo patients and female sex, severe form of vitiligo, and receiving phototherapy. This may suggest that early diagnosis of FMS in vitiligo patients may help in early treatment and subsequently improve patients’ quality of life.

🔖

Bu Makaleye Atıf Yap

KHUDHAIR, O. S., GORIAL, F. I., HAMEED, A. F. (2018). Fibromyalgia Syndrome and Vitiligo: A Novel Association. art, Cilt: 33 - Sayı: 2, 174–180. https://ajindex.com/articles/158939

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Mork PJ, Vasseljen O, Nilsen TI. Association between physical exercise, body mass index, and risk of fibromyalgia: longitudinal data from the Norwegian Nord-Trøndelag Health Study. Arthritis Care Res (Hoboken) 2010;62:611-7.
  2. Karia S, Sousa AD, Shah N, Sonavane S, Bharati A. Psychological Morbidity in Vitiligo-A Case Control Study. JPD 2015;2:1-4.
  3. Sharma N, Koranne RV, Singh RK. Psychiatric morbidity in psoriasis and vitiligo: a comparative study. J Dermatol 2001;28:419-23.
  4. Karelson M, Silm H, Kingo K. Quality of life and emotional state in vitiligo in an Estonian sample: comparison with psoriasis and healthy controls. Acta Derm Venereol 2013;93:446-50.
  5. Erdogan HK, Sas S, Acer E, Bulur I, Altunay IK, Erdem HR. Cutaneous findings in fibromyalgia syndrome and their effect on quality of life. DermSinica 2016;34:131-4.
  6. Bellato E, Marini E, Castoldi F, Barbasetti N, Mattei L, Bonasia DE, et al. Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment. Pain Res Treat 2012;2012:426130. Cakit BD, Taskin S, Nacir B, Unlu I, Genc H, Erdem HR. Comorbidity of fibromyalgia and cervical myofascial pain syndrome. Clin Rheumatol 2010;29:405-11.
  7. Kutlubay Z, Karaku Ö, Engin B, Serdaro¤lu S. Vitiligo as an autoimmune disease. J Turk Acad Dermatol 2012;6:1262. Gawkrodger DJ, Ormerod AD, Shaw L, Mauri-Sole I, Whitton ME, Watts MJ, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol 2008;159:1051-76. González E, Elorza J, Failde I. Fibromyalgia and psychiatric comorbidity: their effect on the quality of life patients. Actas Esp Psiquiatr 2010;38:295-300.
  8. Sharquie KE, Elethawi AM. Common Hypopigmented Skin Disorders in Baghdad Teaching hospital. Iraqi J Comm Med 2011;24:258-60
  9. Osman AM, Elkordufani Y, Abdullah MA. The psychological impact of vitiligo in adult Sudanese patients. Afr J Psychiatry (Johannesbg) 2009;12:284-6.
  10. Aradhya SS, Manjunath K, Kasturi, Somaiah S. Quality of life and psychosocial impact of vitiligo in Indian patients. Pigment International 2015;2:28-33.
  11. Fitzcharles MA, Ste-Marie PA, Goldenberg DL, Pereira JX, Abbey S, Choinière M, et al. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Res Manag 2013;18:119-26.
  12. Turkyilmaz AK, Kurt EE, Karkucak M, Capkin E. Sociodemographic characteristics, clinical signs and quality of life in patients with fibromyalgia. Eurasian J Med 2012;44:88-93. Gözübüyüko¤ullar A, Onan DT, Allı N. Fibromyalgia syndrome in chronic urticaria